scholarly journals hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes

2011 ◽  
Vol 60 (6) ◽  
pp. 809-818 ◽  
Author(s):  
Else M. Inderberg Suso ◽  
Svein Dueland ◽  
Anne-Marie Rasmussen ◽  
Turid Vetrhus ◽  
Steinar Aamdal ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Dendritic Cell ◽  
Cancer Patient ◽  
Complete Response ◽  
Pancreatic Cancer Patient ◽  
Dendritic Cell Vaccination ◽  
Htert Mrna

Exceptional responses in patients with upper gastrointestinal malignancies enrolled in first-in-man studies: 2002-2012.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. 311-311
Author(s):  
Zachary L Reese ◽  
Danielle Tometich ◽  
Shiven B. Patel ◽  
Sunil Sharma ◽  
Ignacio Garrido-Laguna
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Kinase Inhibitor ◽  
Treatment Options ◽  
Progression Free Survival ◽  
Complete Response ◽  
Pancreatic Cancer Patient ◽  
Gastrointestinal Malignancies ◽  
Upper Gastrointestinal

311 Background: First-in-man (FIM) studies test the efficacy and safety of novel therapeutic agents with proven in vitro activity when used for the first time in humans. Patients with advanced upper gastrointestinal malignancies (UGIM) have limited systemic treatment options. We established a database of FIM studies published from 2002-2012 to identify exceptional responders in patients with UGIM. Methods: Using a Scopus search, we compiled a database of published FIM studies enrolling patients with UGIM between 2002 and 2012. We identified exceptional responders to therapy among these patients as a complete response or a partial response lasting at least 6 months. Results: We identified 84 FIM studies enrolling at least one patient with UGIM. In total 554 patients with UGIM were enrolled including 290 pancreatic adenocarcinomas (52.3%), 110 gastric adenocarcinomas (19.9%), 83 esophageal carcinomas (15.0%), 41 hepatocellular carcinomas (7.4%), and 30 cholangiocarcinomas/gallbladder carcinomas (5.4%). One patient with pancreatic cancer treated with bosutinib, a src kinase inhibitor, had a complete response with a progression-free survival (PFS) of 42 months. Four partial responses were reported including one pancreatic cancer patient treated with CHR-3996, a histone deacetylase inhibitor (PFS 12 mo); two pancreatic cancer patients treated with trametinib, a MEK inhibitor (10 and 11.75 mo); and one cholangiocarcinoma patient treated with SB-743921, a kinesin inhibitor (11 mo). Two additional partial responses were noted without available PFS data including one pancreatic cancer patient treated with KOS-1584, a second generation epothilone, and one gastric cancer patient treated with apatinib, a VEGFR-2 inhibitor. Conclusions: Exceptional responses are seen in patients with UGIM enrolled in FIM studies. Actionable genetic aberrations may be driving disease in these patients. Further studies are needed to understand these responses at the molecular level. These molecular studies could open new treatment opportunities for patients with advanced UGIM.

Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report

2021 ◽  
pp. 1-7
Author(s):  
Janna-Lisa Velthaus ◽  
Peter Iglauer ◽  
Ronald Simon ◽  
Carsten Bokemeyer ◽  
Peter Bannas ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Point Mutation ◽  
Kinase Inhibitors ◽  
Point Mutations ◽  
Progression Free Survival ◽  
Pancreatic Cancer Patient ◽  
Targeted Treatment ◽  
Precision Oncology ◽  
Disease Stabilization

<b><i>Introduction:</i></b> The prognosis of pancreatic cancer has improved only modestly in recent years. This is partly due to the lack of development in precision oncology including immune oncology in this entity. Rearrangements of the proto-oncogene tyrosine protein kinase <i>ROS1</i> gene represent driver alterations found especially in lung cancer. Tyrosine kinase inhibitors (TKI) with activity against ROS1 including lorlatinib substantially improved the outcome of this patient population. Anecdotal evidence reports treatment of pancreatic cancer harboring <i>ROS1</i> fusions with ROS1 TKI, but data concerning treatment of patients with <i>ROS1</i> point mutations are lacking. <b><i>Case Presentation:</i></b> This case describes a pancreatic cancer patient harboring a <i>ROS1</i> point mutation that occurred without an underlying <i>ROS1</i> rearrangement and thus not in the resistance situation. The heavily pretreated patient showed a strong decrease of the tumor biomarkers (CA19-9 and CEA) and radiologically a durable stable disease to the targeted treatment with lorlatinib, thereby achieving a progression-free survival of 12 months. <b><i>Conclusion:</i></b> Our data are the first to show a clinical benefit from targeted treatment with ROS1 TKI in a cancer patient with a thus far undescribed <i>ROS1</i> point mutation without a concomitant <i>ROS1</i> rearrangement. Furthermore, they indicate that <i>ROS1</i> could be an oncogenic driver in pancreatic cancer. This subgroup could be eligible for targeted treatments, which may contribute to the urgently needed improvement in patient outcome.

scholarly journals Descriptive Analysis of the Resected Pancreatic Cancer Patient Journey: Findings from a U.S. Real-World Claims-Based Analysis

2016 ◽  
Vol 19 (7) ◽  
pp. A766
Author(s):  
J Kish ◽  
T Maida ◽  
BA Feinberg ◽  
C Biggs ◽  
U Mujumdar ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Real World ◽  
Descriptive Analysis ◽  
Pancreatic Cancer Patient ◽  
Patient Journey

scholarly journals Factors Associated with Ketamine Use in Pancreatic Cancer Patient in a Single Hospice Center

2016 ◽  
Vol 19 (3) ◽  
pp. 249-255
Author(s):  
Kyung Min Kwon ◽  
Yong Joo Lee ◽  
Chang Jin Choi ◽  
Chul Min Kim ◽  
Jo Hi Yoon ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Pancreatic Cancer Patient ◽  
Factors Associated

The effect of pancreatic cancer patient derived serum on macrophage M1/M2 polarization

Pancreatology ◽  
2018 ◽  
Vol 18 (4) ◽  
pp. S147-S148 ◽  
Author(s):  
Matilda Juusola ◽  
Harri Mustonen ◽  
Sanna Vainionpää ◽  
Markus Vähä-Koskela ◽  
Pauli Puolakkainen ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Pancreatic Cancer Patient ◽  
M2 Polarization

Abstract 1456: Efficacy of photo-immunotherapy in combination with surgical resection on a pancreatic cancer patient derived orthotopic xenograft (PDOX)

2015 ◽  
Author(s):  
Yukihiko Hiroshima ◽  
Ali Maawy ◽  
Takashi Murakami ◽  
Nzola De Magalhães ◽  
Daisuke Kawaguchi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Surgical Resection ◽  
Pancreatic Cancer Patient ◽  
Orthotopic Xenograft

Abstract 639: Subtyping of pancreatic cancer patient-derived xenograft tumors and implications for anticancer agent testing

2016 ◽  
Author(s):  
Peter Bronsert ◽  
Tim Kees ◽  
Bruno Zeitouni ◽  
Anne-Lise Peille ◽  
Manuel Landesfeind ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Patient ◽  
Anticancer Agent ◽  
Pancreatic Cancer Patient ◽  
Patient Derived Xenograft
Sign in / Sign up

Export Citation Format

Share Document